Bharat Biotech Considers $500 Million IPO Amid India's Biopharma Push; Sunway Healthcare Files for $736 Million IPO

Bharat Biotech International Ltd, a Hyderabad-based vaccine developer established in 1996, is reportedly considering an initial public offering (IPO) expected to raise around $500 million. The company, known for vaccines including those for COVID-19 and hepatitis B, is evaluating details such as lot sizes and timing. This move aligns with the Indian government's recent Rs 10,000 crore 'Biopharma Shakti' initiative to boost domestic biopharma production over five years, as highlighted in the Union Budget 2026. Separately, Sunway Healthcare has launched a prospectus for an IPO up to $736 million in the US markets.